Physician profile
Michael Eugene Harless
NPI 1972535342
$16,855.80
in general payments reported to CMS, 2019-2025
57 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,501 · 2020: $2,324 · 2021: $3,540 · 2022: $2,770 · 2023: $3,203 · 2024: $2,517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,593 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,593.21 |
| Education | $127.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,244.16 | 2021-2024 | |
| Novo Nordisk INC | $1,572.52 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,080.47 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,035.58 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $988.94 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $957.13 | 2019-2024 | |
| Ironwood Pharmaceuticals, INC | $898.03 | 2019-2024 | Linzess |
| Glaxosmithkline, LLC. | $811.25 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $623.81 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Teva Pharmaceuticals USA, INC. | $614.09 | 2019-2021 | |
| Amgen INC. | $486.23 | 2019-2024 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $457.86 | 2019-2024 | Xifaxan, Trulance |
| Astellas Pharma US INC | $410.70 | 2019-2024 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $384.46 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $382.83 | 2019-2023 | Xarelto |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Harless listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.